Abstract:PURPOSE OF REVIEW: The ability to generate pigs expressing a human complement regulatory protein (hCRP) and/or pigs in which the alpha1,3-galactosyltransferase gene has been knocked out (GT-KO) has largely overcome the barrier of hyperacute rejection of a pig organ transplanted into a primate. However, acute humoral xenograft rejection (AHXR), presenting as microvascular thrombosis and/or consumptive coagulopathy, remains a major hurdle to successful xenotransplantation. This review summarizes recent studies of the coagulation problems associated with xenotransplantation, and discusses potential strategies to overcome them.RECENT PROGRESS: Organ transplantation into nonhuman primates from GT-KO pigs that express a hCRP are not susceptible to hyperacute rejection. Nevertheless, most recipients of GT-KO and/or hCRP transgenic pig organs develop a consumptive coagulopathy, even when the graft remains functioning. This is associated with platelet aggregation, thrombocytopenia, anemia, and a tendency to bleed. Whilst this may reflect an ongoing immune response against the graft, (as exposure to anti-nonGal antibodies in vitro induces procoagulant changes in porcine ECs, even in the absence of complement), histological examination of the graft often shows only minimal features of immune injury, unlike grafts undergoing typical AHXR. Importantly, recent in vitro studies have indicated that the coincubation of porcine endothelial cells (ECs) with human platelets activates the platelets to express tissue factor, independent of a humoral immune response. These observations suggest that the use of organs from GT-KO pigs that express a hCRP may not be sufficient to prevent the development of a coagulation disorder following xenotransplantation, even if complete immunological tolerance can be achieved.SUMMARY: Both thrombotic microangiopathy and systemic consumptive coagulopathy are increasingly recognized as barriers to successful xenotransplantation. The breeding of transgenic pigs with one or more human anticoagulant genes, such as CD39 or tissue factor pathway inhibitor, is anticipated to inhibit the procoagulant changes that take place on the graft ECs, and thus may prevent or reduce platelet activation that arises as a result of immune-mediated injury. The identification of the molecular mechanisms that develop between porcine ECs and human platelets may allow pharmacological approaches to be determined that inhibit the development of thrombotic microangiopathy and consumptive coagulopathy. Hopefully, further genetic modification of the organ-source pigs, combined with systemic drug therapy to the recipient, will prolong graft survival further.

Angiopoietin-1 and Angiopoietin-2 Protect Porcine Iliac Endothelial Cells from Human Antibody-Mediated Complement-Dependent Cytotoxicity Through Phosphatidylinositide 3-Kinase/akt Pathway Activation.

TNF-α Promotes Human Antibody-Mediated Complement-Dependent Cytotoxicity of Porcine Endothelial Cells Through Downregulating P38-mediated Occludin Expression.

Angiopoietin-1 Protects Mesenchymal Stem Cells Against Serum Deprivation and Hypoxia-Induced Apoptosis Through the PI3K/Akt Pathway

Altered expression of eNOS, prostacyclin synthase, prostaglandin G/H synthase, and thromboxane synthase in porcine aortic endothelial cells after exposure to human serum-relevance to xenotransplantation.

Porcine IL‐6, IL‐1β, and TNF‐α Regulate the Expression of Pro‐inflammatory‐related Genes and Tissue Factor in Human Umbilical Vein Endothelial Cells

Klotho attenuated antibody-mediated porcine endothelial cell activation and injury.

Human IL-6, IL-17, IL-1β, and TNF-α differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells

Human IL-17 and TNF-α Additively or Synergistically Regulate the Expression of Proinflammatory Genes, Coagulation-Related Genes, and Tight Junction Genes in Porcine Aortic Endothelial Cells

Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium

A Potential Role of TLR2 in Xenograft Rejection of Porcine Iliac Endothelial Cells: an in Vitro Study

Human PD-L1 overexpression decreases xenogeneic human T-cell immune responses towards porcine kidneys

Coagulation dysregulation as a barrier to xenotransplantation in the primate

P- and E-selectin receptor antagonism prevents human leukocyte adhesion to activated porcine endothelial monolayers and attenuates porcine endothelial damage

Silencing Porcine CMAH and GGTA1 Genes Significantly Reduces Xenogeneic Consumption of Human Platelets by Porcine Livers

Modeling human anti-pig xenoimmune responses in a pig artery tissue grafted humanized mouse model

The Introduction of Human Heme Oxygenase-1 and Soluble Tumor Necrosis Factor-α Receptor Type I With Human IgG1 Fc in Porcine Islets Prolongs Islet Xenograft Survival in Humanized Mice

Potential pathological role of pro‐inflammatory cytokines (IL‐6, TNF‐α, and IL‐17) in xenotransplantation

Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses

Co-expression of HLA-E and HLA-G on genetically modified porcine endothelial cells attenuates human NK cell-mediated degranulation

Human complement activation via the alternative pathway on porcine endothelium initiated by IgA antibodies

Angiopoietin1 Inhibits Mast Cell Activation and Protects Against Anaphylaxis